English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

METHOD: A retrospective review of 71 patients with acromegaly admitted in the Department of Neuroendocrinology, “C.I. Parhon” Institute, Bucharest (2006 – 2012) and treated for at least 6 months with SSA according to the Protocol of the Romanian National House of Health Insurance for patients with acromegaly. In 40 of them data on random serum GH and IGF-1 were available at baseline, after 3 months and at the last evaluation on the same SSA dose. Two patients have been evaluated on 2 different doses of SSA. In the other 31 patients not included in this study, the dosage has been either increased after 3 months – in 21 patients, or evaluated after > 3 months – in 10 patients).

Short-term (3 months) compared to long-term response to somatostatin analogues in acromegaly